Figure 1.1
Distribution of NHANES participants with diabetes, congestive heart failure, & markers of CKD, with GFR estimated by MDRD & CKD-EPI equations
[Download]
Figure 1.1
Distribution of NHANES participants with diabetes, congestive heart failure, & markers of CKD, with GFR estimated by MDRD & CKD-EPI equations
[Download]
Figure 1.3
Cumulative distribution curves of NHANES 2001–2008 participants, by method used to estimate GFR (page 40)
[Download]
Table 1b
Awareness, treatment, & control of hypertension, hypercholesterolemia, HDL, total cholesterol,
& diabetes, by ACR, eGFR, & method used to estimate GFR (percent of NHANES participants)
[Download]
Figure 2.1
Distribution of point prevalent general Medicare (age 65+) & MarketScan (age 50–64) patients with coded diabetes, CKD, CHF, & CVA, 2009
[Download]
Table 2b
Prevalence (%) of recognized CKD, by dataset, year, & age (page 48)
[Download]
Figure 2.6
Probability of microalbumin & creatinine testing in Medicare patients at risk for CKD, (page 50)
[Download]
Figure 2.10
Cumulative probability of a physician visit at month 12 following CKD diagnosis, by physician specialty & dataset (page 54)
[Download]
Figure 2.14
Medicare Part D & MarketScan CKD patients with at least one claim for an ACEI/ARB/renin inhibitor in the 12 months following the disease-defining entry period, by CKD diagnosis code, 2008 (pg 56)
[Download]
Figure 2.16
Medicare Part D & Marketscan CKD pts with at least one claim for a DHP calcium channel blocker in the 12 months following the disease-defining entry period, by CKD diagnosis code, 2008 (page 56)
[Download]
Figure 2.18
Medicare Part D & Marketscan CKD patients with at least one claim for a diuretic in the 12 months following the disease-defining entry period, by CKD diagnosis code, 2008 (page 57)
[Download]
Figure 3.1
Unadjusted & adjusted all-cause hospitalization rates in the Medicare & MarketScan populations, by CKD status (page 61)
[Download]
Figure 3.5
Adjusted rates of hospitalization for cardiovascular disease, by dataset & CKD diagnosis code, 2009 (page 63)
[Download]
Figure 3.6
Adjusted rates of hospitalization for infection, by dataset & CKD diagnosis code, 2009 (page 63)
[Download]
Figure 3.9
Unadjusted & adjusted all-cause mortality rates in Medicare CKD & non-CKD patients, 2009 (page 66)
[Download]
Figure 4.1
Cardiovascular disease in patients with or without chronic kidney disease, 2009 (page 71)
[Download]
Figure 4.7
Prescription drug therapy in patients with CHF, by CKD status , 2008 (page 75)
[Download]
Figure 4.11
Percent of patients treated for CHF, by type of medication & CKD status, 2008 (page75)
[Download]
Figure 5.1
Sources of prescription drug coverage in Medicare enrollees, 2008 (page 79)
[Download]
Figure 5.5
Medicare Part D enrollees, by low income subsidy (LIS) status, 2008 (page 81)
[Download]
Figure 5.13
Medicare Part D enrollees, by low income subsidy (LIS) status, 2008 (page 81)
[Download]
Figure 5.16
Cumulative percent of Part D non-LIS enrollees who reach the coverage gap, by CKD stage, 2008 (page 86)
[Download]
Table 5g
Top 15 drugs used in Medicare Part D enrollees with Stage 3–5 CKD, by frequency & net cost, 2008 (page 88)
[Download]
Figure 6.1
Point prevalent distribution & annual costs of Medicare (fee-for-service) patients, age 65 & older, with diagnosed diabetes, CHF, & CKD, 2009 (page 93)
[Download]
Figure 6.5
Overall expenditures for CKD in the Medicare population (page 95)
[Download]
Figure 6.7
Overall expenditures for CKD & congestive heart failure in the Medicare population (page 95)
[Download]